Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-07275315 AND PF-07264660 IN ADULT PARTICIPANTS WITH MODERATE-SEVERE ATOPIC DERMATITIS

NCT05995964 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05995964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05995964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-07275315 AND PF-07264660 IN ADULT PARTICIPANTS WITH MODERATE-SEVERE ATOPIC DERMATITIS
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Recruiting
Start date
August 22, 2023
Completion date
March 8, 2027
Enrollment
340 (estimated)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis